Sanofi Announces Participation in the Second China International Import Expo with Focus on Innovative Medicines, Vaccines, and Digital Health Solutions

Shanghai, July 26, 2019 /PRNewswire/ -- At the "Pre-Exhibition Supply-Demand Matchmaking Meeting for Exhibitors and Buyers in the Medical Devices and Pharmaceuticals & Healthcare Section of the Second China International Import Expo" held today, Sanofi officially announced its participation in the Second China International Import Expo, to be held from November 5 to 10 at the National Exhibition and Convention Center (Shanghai).

As a global leader in pharmaceuticals and healthcare, this marks Sanofi’s second participation in this prestigious event. At the inaugural China International Import Expo, Sanofi showcased its outstanding global R&D achievements, collaborative progress with partners across and beyond the industry, and its long-term commitment to addressing the health needs of the Chinese people, underscoring the positive role Sanofi plays within China’s healthcare ecosystem.

At this year’s China International Import Expo (CIIE), Sanofi has further expanded its booth space in the Medical Devices and Pharmaceuticals & Healthcare section. Building on its understanding of the health needs of the Chinese people, Sanofi will showcase breakthrough innovative medicines and vaccines that it plans to actively introduce to China in the near future, as well as digital innovative healthcare solutions designed to meet diverse health needs.

"As a“A Trusted Partner in Pharmaceutical and Healthcare for 37 Years, Sanofi is Honored to Participate Again in the China International Import Expo on the Occasion of the 70th Anniversary of the Founding of the People's Republic of China. The CIIE is an Important Platform Showcasing Cutting-Edge Global Scientific and Technological Achievements. Sanofi Will Continue to Actively Participate and Advocate Innovation — We Will Introduce More Than 20 Innovative Drugs and Vaccines by 2025 and Strive to Become the Leading Digital Pharmaceutical and Healthcare Enterprise, Thereby Improving the Health of the Vast Majority of the Chinese People.”Dr. Pius S. Hornstein, President of Sanofi China, stated.

As one of the first multinational pharmaceutical and healthcare companies to enter China, Sanofi has grown alongside the Chinese pharmaceutical and healthcare industry.：More than 9,000 Sanofi employees are rooted in over 2,000 counties and cities across China, providing comprehensive innovative health services to the broad Chinese population:Sanofi strivesPromoting health accessibility, covering a county-level population of 760 million,SanofiThe vaccine provides immunoprophylaxis to more than 12 million members of the Chinese public annually,SanofiSanofi’s medications benefit nearly 10 million patients with diabetes and cardiovascular diseases, over 60,000 cancer patients, and more than 600 patients with rare diseases in China each year. Upholding its commitment to safeguarding the health of 1.4 billion Chinese people, Sanofi continues to expand the scale of its R&D and manufacturing bases in China. In addition to its China R&D Center and Asia-Pacific R&D Headquarters in Shanghai, Sanofi has established a Global R&D Operations Center in Chengdu.，and establish a global research institute in Suzhou.

The China International Import Expo is jointly hosted by the Ministry of Commerce of the People's Republic of China and the Shanghai Municipal People's Government,Therefore,As a national-level expo centered on imports, the first China International Import Expo (CIIE) recorded cumulative intended transactions worth US$57.83 billion. According to data released today at the “Press Conference for the 100-Day Countdown to the Second China International Import Expo,” 61 countries and more than 3,000 enterprises from over 150 countries and regions have confirmed their participation in this year’s CIIE.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not statements of historical facts. These statements include forecasts and estimates and underlying assumptions, statements regarding the Company’s future plans, objectives, intentions, outlook on future financial position, events, operations, services, product development and potential, and statements concerning future performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” and similar expressions are typically used to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that these forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control, which could cause actual results and developments to differ materially from those expressed, implied or projected in the forward-looking information and statements. These risks and uncertainties primarily include uncertainties inherent in research and development, future clinical data and analyses, including post-marketing data and analyses, decisions by regulatory authorities, such as the U.S. Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, medical device, or biological product filed for candidate products, as well as decisions by these agencies concerning product labeling and other matters that may affect the availability and commercial potential of such candidate products; the fact that approval of candidate products does not guarantee commercial success; the approval and commercial success of future alternative therapies; the Group’s ability to benefit from external growth opportunities; trends in exchange rates and prevailing interest rates; cost control policies and their outcomes; the average number of shares outstanding; and Sanofi’s public filings with the U.S. Securities and Exchange Commission (SEC) and the French Financial Markets Authority (AMF) that have been discussed or clarified in the report, including those listed in Table20-FSanofi Annual Report (as of2018Year12Month31day)” under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements.” Except as required by applicable law, Sanofi assumes no obligation to update or revise any forward-looking information or statements.